期刊
BRAIN RESEARCH
卷 1431, 期 -, 页码 97-106出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.brainres.2011.11.007
关键词
Anti-inflammation; Infarction; Neuroprotection; Ischemic stroke; Phosphodiesterase inhibitor
资金
- Ministry for Health and Welfare, Republic of Korea [A080201]
- Asan Institute for Life Sciences, Asan Medical Center, Republic of Korea [2011-396]
Ibudilast, a non-selective phosphodiesterase inhibitor, is clinically used in patients with stroke or dizziness. However, whether the compound exerts a beneficial effect on acute ischemic stroke remains to be established. We used a rat model of transient focal cerebral ischemia using middle cerebral artery occlusion (MCAO) and reperfusion, and explored the effects of ibudilast on infarction size, brain edema, atrophy, and nerve cell death. Neurological outcomes (behavior and mortality) of rats were also assessed. An intravenous administration of ibudilast attenuated the size of cerebral infarction in a dose-dependent manner, with the most significant reduction achieved at the dose of 10 mg/kg. Ibudilast induced a significant reduction in infarct size when administered 30 min before MCAO or 0-2 h after reperfusion, with the largest reduction observed at 30 min before MCAO and 1 h after reperfusion. Ibudilast significantly attenuated brain edema formation, cerebral atrophy and apoptosis of nerve cells preferentially in the cortical penumbra area, and also significantly reduced mortality and improved neurological outcomes. Expression of various inflammatory mediator molecules in both hemispheres was markedly suppressed by ibudilast. we conclude that ibudilast exerts beneficial effects against acute brain ischemia in an animal model. (C) 2011 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据